The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

Autor: Rupert, Bartsch, Brigitte, Mlineritsch, Michael, Gnant, Thomas, Niernberger, Ursula, Pluschnig, Richard, Greil, Catharina, Wenzel, Paul, Sevelda, Josef, Thaler, Margaretha, Rudas, Michael, Pober, Christoph C, Zielinski, Guenther G, Steger, K, Wilthoner
Rok vydání: 2008
Předmět:
Zdroj: Breast Cancer Research and Treatment. 115:373-380
ISSN: 1573-7217
0167-6806
DOI: 10.1007/s10549-008-0132-0
Popis: Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred and fifty patients were included. Time to progression (TTP) was defined as primary endpoint. A multivariate analysis was performed to identify factors significantly associated with TTP. Results Fulvestrant was administered as first-line therapy in 26%, second-line in 49%, and third-line or beyond in 25%. TTP was median 7 months. We observed a response in 15% of patients and 41% had SD ≥ 6 months. First-line treatment and non-visceral metastases were associated with longer TTP. One case of pulmonary embolism was reported. Grade 3 toxicities consisted of joint pain (1.4%), nausea (1.4%) and hot flashes (0.3%). Conclusions Fulvestrant was effective and well tolerated. TTP was superior to other trials, due to the large proportion of first-line patients. Activity is apparently independent of Her2-status.
Databáze: OpenAIRE
Externí odkaz: